Accelerate Diagnostics, Inc (AXDX)

Etorro trading 970x250
Accelerate Diagnostics, Inc (AXDX) Logo

About Accelerate Diagnostics, Inc

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona. Address: 3950 South Country Club Road, Tucson, AZ, United States, 85714

Accelerate Diagnostics, Inc News and around…

Latest news about Accelerate Diagnostics, Inc (AXDX) common stock and company :

Accelerate Diagnostics Schedules Call to Review 3rd Quarter 2021 Results
19 Oct, 2021 Yahoo! Finance

Accelerate Diagnostics, Inc. announced today that management will host a conference call on Tuesday, November 9, 2021, at 4:30 p.m. Eastern Time to review 2021 third quarter financial results.

Insider Buying Could Indicate a Bottom in These 2 Stocks
01 Oct, 2021 Yahoo! Finance

Buying low and selling high may sound too basic to support a stock portfolio, but it has been and always will be a sure way to build profits. The only real trick to it – and it’s admittedly a tough trick to learn – is finding when a stock is at or near the bottom, to buy in. Plenty of stocks fall in price, that’s nothing new in the market. But most times, there’s a good reason, and it’s usually based in fundamental unsoundness. Successful investors will learn some way to sort this chaff from the

Thursday 9/30 Insider Buying Report: SVRA, AXDX
30 Sep, 2021 FinancialContent

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.

3 Stocks Insiders Are Buying
29 Sep, 2021 FinancialContent

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. ...

Get An Even Better Deal On AXDX Than Director Schuler Did
28 Sep, 2021 FinancialContent

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on September 23, Accelerate Diagnostics Inc's Director, Jack W..

The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
28 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Insiders who bought this year lost US$5.2k as Accelerate Diagnostics, Inc. (NASDAQ:AXDX) sheds US$41m in value
28 Sep, 2021 Yahoo! Finance

Insiders who bought US$150k worth of Accelerate Diagnostics, Inc.'s ( NASDAQ:AXDX ) stock at an average buy price of...

Accelerate Diagnostics Announces Agreements to Exchange Approximately $51 Million in Principal Amount of Its 2.50% Convertible Senior Notes due 2023 for Common Stock
23 Sep, 2021 Yahoo! Finance

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 2.50% Convertible Senior Notes due 2023 (the "Notes"). Under the terms of these exchange agreements:

Return on Capital Employed Overview: Accelerate Diagnostics
31 Aug, 2021 FinancialContent

After pulling data from Benzinga Pro it seems like during Q2, Accelerate Diagnostics (NASDAQ:AXDX) posted sales of $2.80 million. ...

58 Biggest Movers From Friday
23 Aug, 2021 FinancialContent

Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares climbed 204.1% to close at $19.16 on Friday. Regencell ...

12 Health Care Stocks Moving In Friday's Intraday Session
20 Aug, 2021 FinancialContent

Gainers Regencell Bioscience (NASDAQ:RGC) shares rose 175.07% to $17.33 during Friday's regular session. As of 12:30 ...

Oversold Conditions For Accelerate Diagnostics
20 Aug, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
06 Aug, 2021 Yahoo! Finance

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -2.86% and -12.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics Reports Second Quarter 2021 Financial Results
05 Aug, 2021 Yahoo! Finance

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2021.

Accelerate Diagnostics Announces CE Mark and Availability in Europe of Fast Antimicrobial Susceptibility Test for Use with Existing ID Systems
03 Aug, 2021 Yahoo! Finance

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that the new IVD configuration of its Accelerate PhenoTest® BC kit has been CE marked and is ready for use in Europe.

This In Vitro Diagnostics Company Is Poised to Capture Its Share of a Growing Market
30 Jul, 2021 FinancialContent

Its new system marks a groundbreaking advance in the field of testing for bloodstream infections.

Accelerate Diagnostics (AXDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
29 Jul, 2021 Yahoo! Finance

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Look Under The Hood: MOON Has 38% Upside
23 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Direxion Moonshot Innovators ETF ETF (MOON), we found that the implied analyst target price for the ETF based upon its underlying holdings is $44.97 per unit.

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
16 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Accelerate Diagnostics Schedules Call to Review 2nd Quarter 2021 Results
15 Jul, 2021 Yahoo! Finance

Accelerate Diagnostics, Inc. announced today that management will host a conference call on Thursday, August 5, 2021, at 4:30 p.m. Eastern Time to review 2021 second quarter financial results.

Up 6% in June, Is Accelerate Diagnostics a Good Buy Now?
08 Jul, 2021 FinancialContent

Investors were encouraged by a recent award the company received in the effort to diagnose and treat sepsis more rapidly.

Accelerate Diagnostics Launches a Fast Antimicrobial Susceptibility Test for Use with Existing ID Systems in the United States
07 Jul, 2021 Yahoo! Finance

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced the launch of a new IVD configuration of its Accelerate PhenoTest® BC kit in the United States. With this launch, the Company now provides two solutions for fast sepsis testing.

New Accelerate Pheno® Landmark Study Validates Important Clinical Benefits to Be Presented at ECCMID 2021
30 Jun, 2021 Yahoo! Finance

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that it will have 3 data presentations from its Improving Outcomes and Antibiotic Stewardship (IOAS) Study at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) to be held July 9–12, 2021. The purpose of this landmark study is to compare data before and after implementation of the Accelerate Pheno system across several hospitals to determine the effects of the system on treating patients with bloodstream infect

The Math Shows MOON Can Go To $43
22 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Direxion Moonshot Innovators ETF ETF (MOON), we found that the implied analyst target price for the ETF based upon its underlying holdings is $43.23 per unit.

TELUS commits $1 million to champion Canadian small business
22 Jun, 2021 Yahoo! Finance

Small business owners can apply to receive $10,000 and personalized local advertising Canadians encouraged to support their favourite small business using #StandWithOwners for a chance to win a $500 gift card VANCOUVER, British Columbia, June 22, 2021 (GLOBE NEWSWIRE) -- In its second year supporting small businesses through its national #StandWithOwners initiative, TELUS is doubling its commitment by investing $1 million to promote these vitally important organizations in 2021. Small business o

TELUS announces pricing of inaugural Sustainability-Linked Bond offering, the first of its kind in Canada
22 Jun, 2021 Yahoo! Finance

$750 million long 10-year notes with 2.85% interest rate, subject to a possible interest rate step-upVANCOUVER, British Columbia, June 21, 2021 (GLOBE NEWSWIRE) -- TELUS announced today it has priced an offering of $750 million of senior unsecured Sustainability-Linked Series CAF notes with a long 10-year maturity. The notes are offered through a syndicate of agents led by RBC Capital Markets, as Lead Structuring Agent and Joint Bookrunner, and Scotiabank, as Co-Structuring Agent and Joint Bookr

Add Up The Parts: MOON Could Be Worth $46
21 May, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Direxion Moonshot Innovators ETF ETF (MOON), we found that the implied analyst target price for the ETF based upon its underlying holdings is $45.82 per unit.

Accelerate Diagnostics to Participate in William Blair 41st Annual Growth Stock Conference on June 3, 2021
19 May, 2021 Yahoo! Finance

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that Chief Executive Officer, Jack Phillips, and Chief Financial Officer, Steve Reichling, will present virtually at the William Blair 41st Annual Growth Stock Conference on Thursday, June 3, 2021 at 12:00 p.m. Central Time.

Accelerate Diagnostics, Inc (AXDX) is a NASDAQ Common Stock listed in , ,

970x250